Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension
Tier: Tier 1 — Foundational Recall

1. Which of the following correctly identifies the two first-line drug classes for isolated systolic hypertension in the elderly and the landmark trials that established them?

A) ACE inhibitors and ARBs are the first-line classes for elderly ISH — established by the MICRO-HOPE and LIFE trials demonstrating superiority over diuretics for stroke prevention in elderly patients.
B) Beta-blockers and ACE inhibitors are the first-line classes for elderly ISH — beta-blockers lower heart rate reducing pulsatile wall stress, and ACEi reduce neurohormonal activation; both SHEP and HYVET tested these classes.
C) Thiazide-like diuretics and non-dihydropyridine CCBs are the first-line classes for elderly ISH — SHEP established chlorthalidone and Syst-Eur established verapamil as the cornerstone agents.
D) Thiazide-like diuretics and dihydropyridine CCBs are the two first-line classes for elderly ISH — SHEP established chlorthalidone-based therapy (36% stroke reduction), and Syst-Eur established DHP CCBs through nitrendipine-based therapy (42% stroke reduction); both classes work effectively through renin-independent mechanisms in the low-renin, volume-dependent hypertension typical of elderly ISH.
E) Aldosterone antagonists and loop diuretics are the first-line classes for elderly ISH — spironolactone was established by PATHWAY-2 as the most effective agent, and furosemide provides superior volume control compared to thiazide diuretics in elderly patients with reduced GFR.

ANSWER: D

Rationale:

The two evidence-based first-line drug classes for elderly ISH are thiazide-like diuretics and dihydropyridine CCBs. SHEP (Systolic Hypertension in the Elderly Program, 1991) enrolled 4,736 patients aged 60 or older with ISH and demonstrated a 36% reduction in stroke with chlorthalidone-based therapy versus placebo — establishing thiazide-like diuretics as cornerstone first-line agents. Syst-Eur (Systolic Hypertension in Europe, 1997) enrolled 4,695 patients aged 60 or older with ISH and demonstrated a 42% reduction in stroke with nitrendipine (a DHP CCB)-based therapy versus placebo — establishing DHP CCBs as an equally effective alternative. Both classes work effectively through renin-independent mechanisms (diuretics reduce volume load; DHP CCBs reduce arteriolar resistance through L-type calcium channel blockade), making them particularly appropriate for the low-renin, volume-dependent hypertension typical of elderly ISH.

Option A: Option A is incorrect because ACEi and ARBs are not the primary first-line agents for elderly ISH — they are less effective as monotherapy in low-renin elderly ISH and lack SHEP/Syst-Eur type ISH-specific trial evidence as single-agent first-line therapy.
Option B: Option B is incorrect because beta-blockers are not first-line for uncomplicated elderly ISH — SHEP used chlorthalidone as the primary agent (atenolol was only a step-2 add-on), and HYVET used indapamide, not a beta-blocker.
Option C: Option C is incorrect because Syst-Eur tested nitrendipine, a dihydropyridine CCB — not verapamil, which is a non-dihydropyridine CCB; non-DHP CCBs have cardiac depressant effects and are not first-line for elderly ISH.
Option E: Option E is incorrect because aldosterone antagonists and loop diuretics are not first-line for elderly ISH — spironolactone's PATHWAY-2 evidence is for resistant hypertension as a fourth-line agent; loop diuretics are not preferred over thiazide-like diuretics for uncomplicated ISH.

2. A 79-year-old woman presents with BP 166/68 mmHg. She has no CKD, no heart failure, and no diabetes. Which of the following is the most appropriate first antihypertensive agent?

A) Lisinopril 5 mg daily — ACEi are preferred in elderly women because they reduce the risk of osteoporosis-related fractures through prostaglandin-mediated calcium metabolism effects.
B) Chlorthalidone 12.5 mg daily — thiazide-like diuretics are first-line for elderly ISH based on SHEP evidence; chlorthalidone is preferred over HCTZ in elderly patients because its longer half-life provides more sustained 24-hour BP control; initiation at the lowest effective dose with sodium and potassium monitoring in 2–4 weeks is appropriate.
C) Spironolactone 25 mg daily — mineralocorticoid receptor antagonists are preferred in elderly women because they simultaneously lower BP and reduce aldosterone-mediated cardiovascular fibrosis.
D) Verapamil 120 mg twice daily — non-DHP CCBs are the preferred calcium channel blocker class in elderly ISH because their negative chronotropy reduces pulse wave velocity and pulse pressure.
E) Atenolol 25 mg daily — cardioselective beta-blockers are first-line for elderly ISH because their reduction in heart rate lowers cardiac output and reduces pulsatile arterial stress.

ANSWER: B

Rationale:

Chlorthalidone 12.5 mg daily is the most appropriate first agent for this 79-year-old woman with uncomplicated ISH. Chlorthalidone is a thiazide-like diuretic with strong ISH-specific evidence from SHEP (which used chlorthalidone as the primary agent and demonstrated 36% stroke reduction). Chlorthalidone is preferred over hydrochlorothiazide in elderly patients because its significantly longer half-life (40–60 hours vs 6–12 hours for HCTZ) provides more sustained 24-hour BP control with less trough-to-peak BP variability, which independently predicts cardiovascular outcomes. Initiating at 12.5 mg (the lowest standard dose) follows the start-low, go-slow principle for elderly patients. Monitoring sodium within 2–4 weeks is specifically required because hyponatremia risk is highest in the first weeks of thiazide therapy — elderly women are at the highest risk group.

Option A: Option A is incorrect because ACEi are not specifically preferred over thiazide-like diuretics or CCBs in elderly uncomplicated ISH — they are less effective as monotherapy in low-renin elderly ISH, and the osteoporosis fracture benefit attributed to prostaglandin effects is not an established pharmacological indication for lisinopril.
Option C: Option C is incorrect because spironolactone is not first-line for elderly ISH — it is a fourth-line agent for resistant hypertension; its anti-aldosterone and cardiovascular antifibrotic properties do not constitute a first-line indication.
Option D: Option D is incorrect because verapamil is a non-DHP CCB — Syst-Eur established DHP CCBs (nitrendipine) for elderly ISH, not non-DHP CCBs; verapamil's negative chronotropy does not specifically reduce pulse wave velocity in the way claimed.
Option E: Option E is incorrect because beta-blockers including atenolol are not first-line for uncomplicated elderly ISH — they are less effective at reducing systolic BP in low-renin ISH; and atenolol is specifically the beta-blocker most avoided in the elderly due to renal accumulation.

3. An 83-year-old man on indapamide 1.25 mg and amlodipine 5 mg has a sitting BP of 144/62 mmHg and a standing BP of 120/50 mmHg at his clinic visit. He has had no falls. He reports mild dizziness on rising from bed in the morning. Which of the following is the most appropriate next step?

A) Add perindopril 2 mg daily — the HYVET regimen specifically requires all three agents (indapamide + amlodipine + perindopril) for maximum cardiovascular protection in the very elderly; adding perindopril completes the evidence-based protocol.
B) Increase amlodipine to 10 mg — his sitting BP of 144 mmHg is above the ESH target of 140–149 mmHg and requires tighter control; the morning dizziness is positional and not a pharmacological concern.
C) Reduce amlodipine to 2.5 mg or reduce indapamide to a half dose — his standing BP of 120/50 mmHg with morning dizziness indicates symptomatic orthostatic hypotension; his sitting SBP of 144 mmHg is already within the ESH 2023 target range of 140–149 mmHg for patients aged 80 or older; dose reduction is the appropriate step to address the orthostatic component while maintaining adequate sitting BP control.
D) Refer for tilt-table testing before making any medication changes — orthostatic hypotension in the elderly must be confirmed by formal tilt-table testing before pharmacological management is adjusted.
E) Add midodrine 5 mg three times daily — midodrine is the first-line pharmacological treatment for all cases of drug-induced orthostatic hypotension in the elderly and should be initiated before any antihypertensive dose adjustment.

ANSWER: C

Rationale:

This patient has symptomatic orthostatic hypotension — a 24 mmHg SBP drop and 12 mmHg DBP drop on standing with morning dizziness, meeting the diagnostic criteria. His sitting SBP of 144 mmHg is already within the ESH 2023 recommended target range of 140–149 mmHg for patients aged 80 or older — there is no pressing reason to push it lower. The standing SBP of 120 mmHg with DBP of 50 mmHg is concerning: the DBP is approaching the threshold of concern for coronary perfusion (below 65 mmHg), and the symptomatic dizziness on rising indicates clinically significant orthostatic hypotension. The appropriate pharmacological response is to reduce the antihypertensive burden — reducing amlodipine from 5 mg to 2.5 mg or reducing indapamide — rather than intensifying therapy. Non-pharmacological measures (slow positional changes, morning hydration, timing of doses) should also be implemented.

Option A: Option A is incorrect because adding a third agent to a patient who already has symptomatic orthostatic hypotension would worsen the orthostatic drop — the HYVET regimen is an evidence framework, not a mandatory three-drug protocol for all patients regardless of clinical status.
Option B: Option B is incorrect because his sitting BP is already at target by ESH 2023 criteria; increasing amlodipine in a patient with symptomatic orthostatic hypotension would worsen the standing BP drop.
Option D: Option D is incorrect because tilt-table testing is not required for clinical diagnosis of orthostatic hypotension in most patients — clinical BP measurement in sitting and standing positions is the standard assessment; tilt-table testing is reserved for unexplained recurrent syncope.
Option E: Option E is incorrect because midodrine — a peripheral alpha-1 agonist — is not first-line for drug-induced orthostatic hypotension; antihypertensive dose reduction and non-pharmacological measures are the primary interventions; midodrine is reserved for refractory cases and can cause dangerous supine hypertension in the elderly.

4. A 74-year-old man with ISH and newly diagnosed atrial fibrillation requiring rate control is on amlodipine 10 mg daily. His BP is 138/72 mmHg and heart rate is 96 bpm at rest. Which of the following correctly addresses both conditions?

A) Add bisoprolol 2.5 mg daily — a cardioselective beta-blocker provides effective rate control in AF through AV nodal beta-1 blockade while adding further BP lowering; bisoprolol is preferred over atenolol in this patient because bisoprolol has dual hepatic and renal elimination and is not renally accumulated to the same degree; monitor for excessive bradycardia given concurrent amlodipine.
B) Switch amlodipine to verapamil — verapamil provides both rate control in AF (AV nodal conduction slowing) and antihypertensive effect through calcium channel blockade; combining verapamil with amlodipine would be dangerous but replacing amlodipine with verapamil is safe.
C) Add digoxin 0.125 mg daily — digoxin is the first-line rate control agent in elderly patients with AF because it does not lower BP and therefore avoids worsening orthostatic hypotension; its positive inotropic effect provides additional cardiovascular protection.
D) Add diltiazem 120 mg daily to the existing amlodipine — combining a non-DHP CCB with a DHP CCB provides complementary rate control and BP lowering without the negative chronotropic risks of beta-blockers in the elderly.
E) No additional pharmacological treatment is needed — a heart rate of 96 bpm in a 74-year-old with AF is within the lenient rate control target of below 110 bpm established by the RACE II trial; amlodipine alone is sufficient for both BP and rate management.

ANSWER: A

Rationale:

This patient has two concurrent clinical needs: AF rate control and continued BP management. His heart rate of 96 bpm at rest is above the lenient rate control target, and his amlodipine provides arteriolar vasodilation (antihypertensive) but has minimal AV nodal rate-controlling effect (DHP CCBs have high vascular selectivity). Adding a cardioselective beta-blocker addresses both needs: bisoprolol provides AV nodal rate control through beta-1 blockade and additional BP lowering through reduced cardiac output. Bisoprolol is preferred over atenolol in elderly patients because it has dual elimination — approximately 50% hepatic metabolism and 50% renal excretion — so as eGFR declines with age, hepatic elimination partially compensates, reducing the accumulation risk seen with atenolol (greater than 85% renally excreted). Monitoring for bradycardia is important as amlodipine has some mild cardiac effects at 10 mg.

Option B: Option B is incorrect because switching to verapamil provides rate control but loses the established DHP CCB-specific evidence for elderly ISH from Syst-Eur; and verapamil combined with amlodipine in a previous patient scenario showed additive cardiac suppression risk — the substitution avoids combination but loses ISH-specific benefit.
Option C: Option C is incorrect because digoxin is not first-line for AF rate control — it is reserved for patients intolerant of beta-blockers and non-DHP CCBs, provides poor rate control during exercise, has a narrow therapeutic index particularly hazardous in elderly patients with reduced renal clearance, and its positive inotropic effect is not a cardiovascular protection rationale for rate control.
Option D: Option D is incorrect because combining diltiazem (non-DHP CCB) with amlodipine (DHP CCB) risks additive cardiac calcium channel suppression causing significant bradycardia and AV block — this combination is specifically to be avoided in elderly patients with potential conduction disease.
Option E: Option E is incorrect because a heart rate of 96 bpm is within the lenient RACE II target (below 110 bpm) and technically acceptable — however, the question asks what correctly addresses both conditions; amlodipine does not provide meaningful rate control, and a resting HR of 96 leaves little reserve; adding rate control in a symptomatic patient is clinically appropriate.

5. Which of the following correctly identifies the HYVET trial drug regimen and the BP target achieved in the active treatment arm?

A) HYVET used amlodipine 5–10 mg ± lisinopril 5–10 mg; the mean achieved SBP in the active treatment arm was 128 mmHg — demonstrating that aggressive BP lowering below 130 mmHg is achievable and safe in patients aged 80 or older.
B) HYVET used chlorthalidone 12.5–25 mg ± atenolol 25–50 mg; the mean achieved SBP was 155 mmHg; HYVET established that the target SBP in the very elderly is 150–160 mmHg rather than the lower targets used in younger patients.
C) HYVET used indapamide 1.5 mg SR ± perindopril 2–4 mg with a target SBP of 150 mmHg; the mean achieved SBP in the active treatment arm was 143.5 mmHg, demonstrating that moderate BP reduction (not aggressive below-130 targeting) is sufficient to produce substantial cardiovascular and mortality benefit in patients aged 80 or older.
D) HYVET used lisinopril 10 mg ± hydrochlorothiazide 25 mg; the mean achieved SBP was 138 mmHg; HYVET established that ACEi-based therapy is the preferred regimen for the very elderly.
E) HYVET used indapamide 1.5 mg SR ± perindopril 2–4 mg; the mean achieved SBP in the active treatment arm was 143.5 mmHg; the trial demonstrated a 21% reduction in all-cause mortality, 64% reduction in heart failure, and — crucially — fewer serious adverse events in the active treatment group than placebo, directly refuting concerns that antihypertensive treatment in patients aged 80 or older is too risky.

ANSWER: E

Rationale:

HYVET (Hypertension in the Very Elderly Trial, 2008) used indapamide 1.5 mg SR (a thiazide-like diuretic in sustained-release formulation) as the backbone agent, with perindopril 2–4 mg (an ACEi) added if the SBP target of 150 mmHg was not achieved on indapamide alone. The mean achieved SBP in the active treatment arm was 143.5 mmHg — a moderate reduction that proved sufficient for substantial benefit. Key results: 30% reduction in stroke (primary endpoint, p=0.06 — trend), 21% reduction in all-cause mortality (p=0.02 — significant), 64% reduction in heart failure (highly significant), and 23% reduction in cardiovascular death. The finding that serious adverse events were fewer in the active treatment arm than in the placebo arm was a particularly impactful result — it directly addressed the clinical concern that treating hypertension in patients aged 80 or older is too dangerous. Option C is correct in identifying the regimen and achieved SBP but is incomplete — it omits the crucial finding about fewer serious adverse events in the treatment arm; option E is more complete.

Option A: Option A is incorrect because HYVET used indapamide ± perindopril, not amlodipine ± lisinopril; and the achieved SBP was 143.5 mmHg, not 128 mmHg — the HYVET evidence base supports moderate BP reduction, not below-130 targeting in the very elderly.
Option B: Option B is incorrect because HYVET used indapamide ± perindopril, not chlorthalidone ± atenolol; atenolol was used in SHEP as a step-2 add-on but was not the HYVET regimen.
Option D: Option D is incorrect because HYVET used indapamide ± perindopril, not lisinopril ± HCTZ; and the achieved SBP was 143.5 mmHg, not 138 mmHg.

6. A 76-year-old man with ISH, stable angina, and a baseline DBP of 64 mmHg is on amlodipine 5 mg daily. His physician wants to add a second antihypertensive to achieve SBP below 140 mmHg. Which of the following is the most important pharmacological caution for this patient?

A) The primary caution is hyperkalemia — adding any RAAS inhibitor to an elderly man with angina significantly increases potassium to dangerous levels due to reduced renal aldosterone clearance in elderly CAD patients.
B) The primary caution is reflex tachycardia — adding chlorthalidone to amlodipine produces a combined vasodilatory effect that triggers marked reflex tachycardia in elderly patients with angina, worsening myocardial oxygen demand.
C) The primary caution is CYP3A4 interaction — chlorthalidone and perindopril are both CYP3A4 inhibitors that significantly raise amlodipine plasma concentrations when added, requiring amlodipine dose reduction before any second agent is initiated.
D) The primary caution is the J-curve — his baseline DBP of 64 mmHg is already near the 65 mmHg threshold of concern for coronary perfusion in elderly patients with CAD; any further reduction in DBP from adding a second antihypertensive risks reducing coronary diastolic perfusion below the critical threshold, increasing myocardial ischemia risk; the antihypertensive should be chosen and titrated carefully with attention to standing DBP and symptoms of coronary underperfusion.
E) The primary caution is immune activation — elderly patients with stable angina have elevated baseline inflammatory markers; adding a second antihypertensive triggers a cytokine-mediated BP rebound within 48 hours that is more pronounced than any initial BP-lowering effect.

ANSWER: D

Rationale:

This patient's baseline DBP of 64 mmHg already places him near the clinically important threshold of 65 mmHg below which coronary diastolic perfusion may be compromised — the J-curve phenomenon. Coronary perfusion depends on diastolic BP because the left ventricular myocardium is perfused during diastole (during systole, intramyocardial tension occludes the coronary microcirculation). In patients with stable angina and likely underlying coronary artery disease, the coronary perfusion reserve may be already reduced by stenotic lesions. If adding a second antihypertensive further reduces DBP below 65 mmHg (particularly during the standing position where DBP is already lower than sitting), the risk of myocardial ischemia increases substantially — manifesting as worsening angina, exercise intolerance, or silent ischemia. The management implication: the second agent should be titrated cautiously with close attention to standing (not just sitting) DBP, with the target of maintaining DBP above 65 mmHg; the patient should be counseled to report worsening angina or exertional symptoms.

Option A: Option A is incorrect because while hyperkalemia is a concern when adding RAAS inhibitors to elderly patients with CKD, it is not specifically driven by reduced aldosterone clearance in elderly CAD patients as described; and it is not the most important pharmacological caution in this specific clinical scenario where DBP is already marginal.
Option B: Option B is incorrect because chlorthalidone does not produce marked reflex tachycardia — it is a diuretic, not a vasodilator; reflex tachycardia is primarily associated with direct arteriolar vasodilators (hydralazine, short-acting nifedipine).
Option C: Option C is incorrect because chlorthalidone and perindopril are not CYP3A4 inhibitors — chlorthalidone is minimally metabolized, and perindopril is a prodrug hydrolyzed to perindoprilat without significant CYP involvement; they do not elevate amlodipine concentrations through CYP inhibition.
Option E: Option E is incorrect because cytokine-mediated BP rebound from adding antihypertensives is pharmacologically fabricated — no such immune activation mechanism is established.

7. A 78-year-old woman with ISH is taking atenolol 50 mg daily, started by a previous provider. She has no AF, no HFrEF, and no prior MI. Her eGFR is 44 mL/min/1.73m² and her heart rate is 54 bpm. Her BP is 148/74 mmHg. Which of the following is the most appropriate pharmacological change?

A) Increase atenolol to 100 mg daily — her BP of 148/74 mmHg is above the ESH target for her age and the dose should be maximized before switching agents.
B) Taper and discontinue atenolol; substitute amlodipine 5 mg or chlorthalidone 12.5 mg — atenolol has no compelling indication in this patient (no AF, no HFrEF, no post-MI), is renally eliminated and accumulating with eGFR of 44 mL/min/1.73m² causing bradycardia (HR 54 bpm), and is not a preferred first-line agent for elderly ISH; the substitution addresses both the BP control and the pharmacokinetic problem.
C) Add amlodipine 5 mg to atenolol — the combination provides complementary mechanisms; atenolol should be continued because abrupt withdrawal causes dangerous rebound hypertension in all elderly patients.
D) Switch atenolol to bisoprolol — bisoprolol has dual elimination and is safer in CKD; maintaining a beta-blocker is essential for cardiovascular protection in elderly ISH patients regardless of whether a compelling indication exists.
E) Add diltiazem 180 mg daily to atenolol for additional rate control and antihypertensive effect — the combination of diltiazem and atenolol provides synergistic bradycardia that is beneficial in elderly ISH patients with fast resting heart rates.

ANSWER: B

Rationale:

This patient has atenolol prescribed without a compelling indication (no AF, no HFrEF, no prior MI) — the only validated reasons to use a beta-blocker in elderly hypertension. Atenolol is renally eliminated (greater than 85% excreted unchanged in urine) and is accumulating at an eGFR of 44 mL/min/1.73m² — producing a resting heart rate of 54 bpm that impairs cardiac reserve and increases falls risk from reduced cardiovascular compensation during positional changes. The appropriate management is to taper and discontinue atenolol (gradual tapering over 2–4 weeks to avoid rebound tachycardia and BP surge, not abrupt cessation) and substitute a first-line agent for elderly ISH — amlodipine 5 mg or chlorthalidone 12.5 mg, each with specific landmark trial evidence for elderly ISH.

Option A: Option A is incorrect because increasing atenolol at eGFR 44 mL/min/1.73m² would further accumulate the drug and worsen the bradycardia — the pharmacokinetic problem is accumulation, not insufficient dosing.
Option C: Option C is incorrect because adding amlodipine to atenolol without addressing the root problem (atenolol without indication + accumulation causing bradycardia) leaves the patient on an inappropriate agent; and abrupt withdrawal causing dangerous rebound is a concern for beta-blockers but does not prevent planned gradual tapering.
Option D: Option D is incorrect because maintaining any beta-blocker is not essential for elderly ISH without a compelling indication — the premise that beta-blockers provide cardiovascular protection in elderly ISH regardless of indication is not evidence-based; bisoprolol is preferred over atenolol when a beta-blocker is genuinely required, but switching to bisoprolol does not address the absence of indication.
Option E: Option E is incorrect because combining diltiazem with atenolol creates a dangerous risk of excessive AV nodal suppression and severe bradycardia — this combination is contraindicated in patients with a resting heart rate already at 54 bpm; synergistic bradycardia is a harm, not a benefit.

8. A 71-year-old man with ISH, benign prostatic hyperplasia (BPH), and BP of 162/74 mmHg on chlorthalidone 12.5 mg daily asks whether his BPH medication (tamsulosin 0.4 mg daily) interacts with his antihypertensive. Which of the following best addresses this question?

A) Tamsulosin and chlorthalidone interact pharmacokinetically through shared CYP3A4 metabolism — concurrent use raises chlorthalidone plasma concentrations by 60%, requiring dose reduction to 6.25 mg when tamsulosin is co-administered.
B) Tamsulosin and chlorthalidone have no clinically meaningful interaction — both drugs lower BP through completely independent mechanisms with no pharmacodynamic additive or synergistic effects; no monitoring change is required.
C) Tamsulosin (an alpha-1 blocker selective for the prostate) can produce additive pharmacodynamic hypotension when combined with any antihypertensive through complementary vasodilatory effects; elderly men are at particular risk for orthostatic hypotension from this combination; standing BP should be assessed and the patient counseled about slow positional changes and fall precautions; if significant orthostatic hypotension develops, tamsulosin dose reduction or substitution with a 5-alpha reductase inhibitor should be considered.
D) Tamsulosin blocks urethral alpha-1 receptors exclusively with no systemic vascular effects — it is pharmacologically equivalent to a topical drug and has no interaction with systemic antihypertensives; no monitoring is required.
E) Chlorthalidone should be switched to an alpha-1 blocker (doxazosin) — combining two agents with prostatic alpha-1 blockade (tamsulosin plus doxazosin) provides superior BPH symptom control and allows chlorthalidone to be stopped entirely.

ANSWER: C

Rationale:

Tamsulosin is a highly uroselective alpha-1A receptor blocker — it preferentially blocks the alpha-1A subtype predominant in the prostate and bladder neck, which is why it has less systemic vasodilatory effect compared with non-selective alpha-1 blockers like doxazosin or terazosin. However, "uroselective" does not mean pharmacologically systemic-effect-free — tamsulosin still has some systemic alpha-1 blockade, producing vasodilatory effects that can cause orthostatic hypotension, particularly when combined with antihypertensives. This pharmacodynamic interaction — additive hypotension from two vasodilatory agents (tamsulosin's alpha-1 blockade + chlorthalidone's volume depletion) — is well-documented, especially in elderly men who already have reduced baroreceptor sensitivity. The initial doses of alpha-1 blockers (including tamsulosin) can cause particularly significant orthostatic effects. Management: assess standing BP, counsel on slow positional changes and fall precautions, and monitor for orthostatic symptoms.

Option A: Option A is incorrect because chlorthalidone is minimally hepatically metabolized and not significantly a CYP3A4 substrate; tamsulosin does not substantially inhibit CYP3A4; the pharmacokinetic interaction described is fabricated.
Option B: Option B is incorrect because the additive pharmacodynamic hypotensive interaction between alpha-1 blockers and antihypertensives is clinically real and well-documented — dismissing it without monitoring is clinically inappropriate.
Option D: Option D is incorrect because tamsulosin does have systemic vascular effects despite its uroselective properties — orthostatic hypotension is a documented adverse effect in clinical trials of tamsulosin, particularly in elderly patients on antihypertensive therapy.
Option E: Option E is incorrect because switching chlorthalidone to doxazosin (a non-selective alpha-1 blocker) would exchange a proven first-line ISH agent for an agent that ALLHAT demonstrated produces more cardiovascular events than chlorthalidone; combining two alpha-1 blockers is also not a recognized BPH treatment strategy.

9. Which of the following correctly describes the "start low, go slow" principle as it applies to antihypertensive prescribing in elderly patients, and why it differs from prescribing in younger adults?

A) In elderly patients, antihypertensives should be initiated at approximately half the standard starting dose used in younger adults (e.g., chlorthalidone 6.25 mg, amlodipine 2.5 mg, perindopril 2 mg) with titration every 4–6 weeks rather than every 2–4 weeks — this conservative approach is warranted because elderly patients have reduced physiological reserve to tolerate sudden BP changes, reduced baroreceptor sensitivity predisposing to orthostatic hypotension, impaired renal and hepatic drug clearance increasing plasma drug concentrations, and are more susceptible to adverse effects including falls, AKI, and electrolyte disturbances; second agents are added only after confirming tolerance and stability of the first agent.
B) The start-low, go-slow principle applies only to centrally acting agents (clonidine, methyldopa) in the elderly — all other antihypertensive classes can be initiated at standard adult doses in elderly patients because their pharmacokinetics are unchanged by normal aging.
C) The start-low, go-slow principle requires using only one antihypertensive for life in elderly patients — once a single agent is started and tolerated, no second agent should ever be added regardless of BP levels, because polypharmacy in the elderly invariably causes harm that outweighs any additional BP-lowering benefit.
D) The start-low, go-slow principle refers exclusively to BP measurement — BP should be measured more frequently in elderly patients (daily for 6 weeks) before any medication is started; the actual drug dosing is identical to younger adults once the decision to treat is made.
E) In elderly patients, antihypertensives should be started at maximum tolerated doses to achieve target BP within the first week — elderly patients have greater cardiovascular risk than younger patients and therefore require faster BP control; the start-low, go-slow principle was derived from studies in younger patients and does not apply above age 75.

ANSWER: A

Rationale:

The start-low, go-slow principle in elderly antihypertensive prescribing is a foundational geriatric pharmacology concept addressing the multiple age-related changes that alter drug pharmacokinetics and pharmacodynamics. Starting at low doses: initiating chlorthalidone at 6.25–12.5 mg (rather than the standard 25 mg), amlodipine at 2.5 mg (rather than 5 mg), or perindopril at 2 mg allows the clinician to identify adverse effects (orthostatic hypotension, hyponatremia, AKI) at a lower drug burden. Going slow in titration: extending titration intervals to every 4–6 weeks (rather than every 2–4 weeks in younger patients) gives the elderly patient's physiology more time to equilibrate to each dose change; it allows early adverse effects to become apparent before the next dose escalation adds further pharmacological burden. The pharmacological rationale: reduced baroreceptor sensitivity means abrupt BP changes cause greater orthostatic hypotension; reduced renal clearance means drug accumulation occurs at standard doses; reduced hepatic first-pass metabolism increases bioavailability of metabolized drugs; reduced lean body mass reduces the volume of distribution; and increased CNS sensitivity amplifies neurological adverse effects. Sequential agent addition rather than combination initiation allows attribution of adverse effects to a specific drug.

Option B: Option B is incorrect because start-low, go-slow applies to all antihypertensive classes in elderly patients, not only to centrally acting agents — and pharmacokinetics are substantially altered by normal aging across multiple parameters.
Option C: Option C is incorrect because elderly patients frequently require combination therapy to achieve BP targets — the start-low, go-slow principle addresses dosing and titration speed, not a prohibition on combination therapy.
Option D: Option D is incorrect because start-low, go-slow refers specifically to drug dosing — starting at low drug doses and titrating slowly — not to BP measurement frequency.
Option E: Option E is incorrect because rapid dose escalation to maximum doses in the first week is antithetical to safe geriatric prescribing — it maximizes adverse effect risk in a population with the least physiological reserve; the principle applies most strongly above age 75, not exclusively in younger patients.

10. A 68-year-old man with ISH is started on clonidine 0.1 mg twice daily by a covering provider for resistant hypertension. His primary physician reviews the regimen. Which of the following best identifies the concern with clonidine in this patient?

A) Clonidine is appropriate in elderly patients because it acts centrally to reduce sympathetic output without peripheral vascular effects — it is actually the safest antihypertensive in the elderly because it does not cause orthostatic hypotension.
B) Clonidine causes hyperkalemia through central alpha-2 agonism reducing aldosterone secretion — the primary monitoring requirement is weekly potassium, not BP or cognitive function.
C) Clonidine should be replaced with methyldopa — methyldopa has superior cognitive safety in elderly patients because it does not cross the blood-brain barrier, unlike clonidine; both are centrally acting agents but methyldopa is peripherally selective.
D) Clonidine is appropriate for resistant hypertension only if it is prescribed as a transdermal patch — oral clonidine has unpredictable absorption in elderly patients; the patch formulation provides consistent plasma levels without rebound risk.
E) Clonidine is generally avoided in elderly patients because of its CNS adverse effects (sedation, cognitive impairment, depression, falls risk from drowsiness) and particularly because of rebound hypertension on missed doses or abrupt discontinuation — elderly patients with poor medication adherence, variable pharmacy access, or cognitive impairment are at high risk for clinically significant rebound hypertension that can precipitate stroke or MI; the prescribing physician should plan a gradual taper and substitute a first-line agent.

ANSWER: E

Rationale:

Clonidine is classified among the centrally acting antihypertensives (along with methyldopa) that are generally avoided in elderly patients and used only as last-resort adjuncts. The central alpha-2 agonism reduces sympathetic outflow effectively but produces CNS adverse effects that are disproportionately harmful in elderly patients: sedation and drowsiness (increasing falls risk), cognitive impairment (worsening or unmasking dementia in susceptible patients), and depression. The most serious concern specific to clonidine is rebound hypertension on missed doses or abrupt discontinuation. Clonidine acts centrally to suppress sympathetic outflow; when the drug is suddenly removed (missed doses, supply interruption, abrupt discontinuation), the suppressed sympathetic system rebounds with a surge of norepinephrine release — producing a hypertensive crisis that can be severe and sustained. In elderly patients with CAD, this rebound can precipitate acute MI or stroke. Elderly patients are at particular risk because of the factors that impair adherence: cognitive impairment, polypharmacy complexity, irregular pharmacy access, and caregiver dependency. The plan: taper clonidine gradually over several weeks while introducing or uptitrating a first-line agent.

Option A: Option A is incorrect because clonidine does cause orthostatic hypotension — central sympathetic reduction impairs the cardiovascular response to position change; it is not the safest antihypertensive in the elderly.
Option B: Option B is incorrect because clonidine-induced hyperkalemia through aldosterone suppression is not a clinically significant primary concern — the dominant concerns are CNS adverse effects and rebound hypertension; weekly potassium monitoring is not the primary monitoring requirement.
Option C: Option C is incorrect because methyldopa is also a centrally acting agent associated with significant sedation, cognitive effects, and other adverse effects in the elderly — it is not a safer alternative to clonidine; and methyldopa does cross the blood-brain barrier (this is essential to its mechanism as a CNS alpha-2 agonist).
Option D: Option D is incorrect because transdermal clonidine does not eliminate the rebound hypertension concern — patch discontinuation or patch detachment still produces rebound; and oral absorption of clonidine is generally predictable.

11. A 77-year-old woman on chlorthalidone 12.5 mg daily presents with serum sodium 129 mEq/L, potassium 3.4 mEq/L, and creatinine 1.1 mg/dL (baseline 0.9 mg/dL). She is mildly symptomatic with fatigue and mild confusion. Which of the following best describes the immediate management?

A) Continue chlorthalidone and add oral sodium supplementation tablets — mild hyponatremia from thiazides always self-corrects within 72 hours as ADH is suppressed by rising osmolality; supplemental sodium accelerates the correction.
B) Increase chlorthalidone to 25 mg — the hyponatremia indicates insufficient natriuresis is driving the ADH response; higher chlorthalidone dose will reduce the ADH stimulus.
C) Add fludrocortisone 0.1 mg daily — fludrocortisone's mineralocorticoid activity will retain sodium and correct the hyponatremia while the chlorthalidone continues to provide antihypertensive benefit.
D) Stop chlorthalidone; monitor and correct the hyponatremia with fluid restriction or cautious isotonic saline as clinically indicated; check the rate of hyponatremia onset (acute vs. chronic) to guide correction speed; after sodium normalizes, consider substituting amlodipine as the antihypertensive to avoid repeating the thiazide-induced hyponatremia.
E) Administer tolvaptan (a vasopressin receptor antagonist) — tolvaptan directly blocks ADH's renal effect and is the first-line pharmacological treatment for thiazide-induced hyponatremia; it corrects the free water retention without requiring chlorthalidone discontinuation.

ANSWER: D

Rationale:

Symptomatic hyponatremia (sodium 129 mEq/L with fatigue and mild confusion) from chlorthalidone requires immediate discontinuation of the causative agent. The pharmacological mechanism — NCC inhibition → natriuresis → volume contraction → ADH stimulation → free water retention — can only be interrupted by stopping the drug; continuing chlorthalidone while attempting sodium correction is pharmacologically counterproductive. Once chlorthalidone is stopped, management of the hyponatremia itself depends on the chronicity and rate of fall: if the hyponatremia developed gradually (more than 48 hours), correction must not exceed 8–10 mEq/L per 24 hours to avoid osmotic demyelination syndrome (central pontine myelinolysis); fluid restriction (for dilutional hyponatremia) or cautious isotonic saline administration can be used depending on volume status. After sodium normalizes, the antihypertensive plan must avoid repeating thiazide exposure — substituting amlodipine 5 mg (or another non-thiazide first-line agent) is appropriate for continued ISH management.

Option A: Option A is incorrect because a sodium of 129 mEq/L with symptoms is not a self-correcting mild condition requiring only supplemental sodium — it requires the causative drug to be stopped; and oral sodium supplementation without addressing the ongoing ADH-mediated free water retention does not correct dilutional hyponatremia.
Option B: Option B is incorrect because increasing the chlorthalidone dose would worsen natriuresis and amplify the ADH stimulus — the hyponatremia would deepen, not improve.
Option C: Option C is incorrect because adding fludrocortisone while continuing chlorthalidone creates a pharmacological conflict — fludrocortisone's sodium-retaining effect partially opposes the natriuresis, but the underlying ADH-mediated water retention would persist; the correct approach is to stop the causative drug.
Option E: Option E is incorrect because tolvaptan (a V2 receptor antagonist) is used for euvolemic and hypervolemic hyponatremia (SIADH, heart failure), not specifically for thiazide-induced hyponatremia — thiazide-induced hyponatremia is managed by drug discontinuation and supportive correction; tolvaptan is not first-line and carries risks of overly rapid correction.

12. Which of the following correctly describes why the ESH 2023 guideline recommends a higher SBP target (140–149 mmHg) for patients aged 80 or older, compared with the ACC/AHA 2017 target of below 130/80 mmHg for adults aged 65 or older?

A) ESH 2023 is a less evidence-based guideline than ACC/AHA 2017 — the higher ESH target reflects European conservatism rather than clinical evidence; clinicians in the US should follow ACC/AHA targets exclusively.
B) The ESH target of 140–149 mmHg for patients aged 80 or older reflects the HYVET evidence base — HYVET achieved a mean SBP of 143.5 mmHg in the active treatment arm and demonstrated substantial benefit at this level; ESH gives greater weight to frailty, the J-curve risk from excessive DBP lowering, and the SPRINT measurement methodology caveat (AOBP values approximately 5–10 mmHg lower than conventional office measurement, meaning SPRINT's 120 mmHg target corresponds to approximately 130 mmHg by standard measurement); the higher target reflects a different evidence weighting, not lower evidence standards.
C) ESH 2023 recommends the higher target because European patients aged 80 or older have lower cardiovascular risk than North American patients of the same age — the risk reduction from aggressive BP lowering is smaller in European populations.
D) ESH 2023 and ACC/AHA 2017 are identical in their targets for patients aged 80 or older — both recommend SBP below 130 mmHg; the apparent difference is due to a translation error between European and North American BP measurement conventions.
E) ESH 2023 recommends the higher target because all patients aged 80 or older are considered frail and therefore require the relaxed target — CFS assessment is not performed in the ESH framework; age 80 alone is the criterion for the higher target without any individualization.

ANSWER: B

Rationale:

The divergence between ESH 2023 and ACC/AHA 2017 targets for the very elderly reflects genuine differences in evidence interpretation and clinical priority weighting — not a quality hierarchy. ESH 2023's recommendation of 140–149 mmHg for patients aged 80 or older is grounded in: the HYVET trial, which demonstrated mortality and heart failure benefit at a mean achieved SBP of 143.5 mmHg — the most directly applicable trial evidence for the very elderly; the J-curve risk, where excessive DBP lowering in elderly patients with CAD and already-low diastolic pressures risks coronary underperfusion; the SPRINT measurement caveat, where AOBP values are 5–10 mmHg lower than conventional office measurement (SPRINT's 120 mmHg target corresponds to approximately 130 mmHg by standard measurement — reducing the apparent gap between the two guidelines); and frailty individualization, where a blanket below-130 mmHg target in patients aged 80 or older disregards the substantial heterogeneity in functional status and adverse-event risk in this age group. Both guidelines agree that treatment is beneficial and indicated — they differ in how aggressively to target and how much to individualize.

Option A: Option A is incorrect because ESH 2023 is a rigorously evidence-based guideline — the different target reflects genuine evidence weighting differences, not conservatism or lesser evidence standards; US clinicians routinely integrate both guidelines.
Option C: Option C is incorrect because the different target does not reflect population-level cardiovascular risk differences between European and North American patients — it reflects differential evidence weighting.
Option D: Option D is incorrect because the guidelines are genuinely different — ACC/AHA 2017 recommends below 130/80 mmHg for community-dwelling adults aged 65 or older, while ESH 2023 recommends 140–149 mmHg specifically for patients aged 80 or older; these are real, clinically meaningful differences.
Option E: Option E is incorrect because ESH 2023 does not treat all patients aged 80 or older as uniformly frail — the guideline explicitly recommends frailty assessment and individualization, with lower targets (130–139 mmHg) considered in fit older patients who tolerate them without adverse effects.

13. A 75-year-old woman with ISH develops bilateral ankle edema four months after starting amlodipine 10 mg daily. Her BP is 132/68 mmHg — at target. The edema is uncomfortable but she has no dyspnea, no elevated JVP, and no weight gain beyond 1 kg. Which of the following is the most pharmacologically appropriate response?

A) Stop amlodipine immediately and switch to atenolol — CCBs cause irreversible ankle edema from permanent lymphatic damage; the only definitive solution is complete class change.
B) Add furosemide 20 mg daily — loop diuretics are the first-line treatment for CCB-induced ankle edema; furosemide counteracts the hemodynamic edema by increasing urinary fluid output.
C) Add perindopril 4 mg daily or switch to perindopril plus a lower amlodipine dose — RAAS inhibitor-induced venodilation reduces the pre-capillary/post-capillary pressure imbalance caused by amlodipine's arteriolar vasodilation, reducing interstitial fluid accumulation; alternatively, reducing amlodipine to 5 mg may partially resolve the edema while accepting some loss of BP control; her BP of 132/68 mmHg provides some room to accept a modest trade-off.
D) Reassure the patient and continue amlodipine at the same dose — CCB-induced ankle edema is entirely benign and never progresses; no pharmacological adjustment is ever required.
E) Add spironolactone 25 mg daily — mineralocorticoid receptor blockade directly counteracts the sodium-retaining effect of CCBs and is the first-line treatment for CCB-induced edema through its natriuretic and aldosterone-blocking mechanism.

ANSWER: C

Rationale:

CCB-induced peripheral edema (from amlodipine's arteriolar vasodilation without equivalent venodilation, causing elevated capillary hydrostatic pressure and interstitial fluid accumulation) is best managed pharmacologically by adding a RAAS inhibitor. ACEi and ARBs produce venodilation through reduction of angiotensin II-mediated venular tone — this specifically addresses the post-capillary component of the hemodynamic imbalance, helping restore the pre-capillary/post-capillary pressure equilibrium and facilitating interstitial fluid reabsorption. This is the pharmacological rationale for the CCB + ACEi/ARB combination being particularly effective for both BP control and edema reduction — observed in the ASCOT-BPLA trial where the amlodipine + perindopril combination produced less edema and better outcomes than other combinations. Alternatively, reducing amlodipine from 10 mg to 5 mg reduces the degree of arteriolar vasodilation and the magnitude of capillary pressure elevation — her current BP of 132/68 mmHg allows some tolerance for a modest BP increase with dose reduction.

Option A: Option A is incorrect because CCB-induced edema does not represent permanent lymphatic damage — it is a reversible hemodynamic phenomenon; switching to atenolol exchanges a first-line ISH agent for a non-first-line agent with multiple adverse effects in elderly patients.
Option B: Option B is incorrect because furosemide treats the edema symptomatically through volume depletion (natriuresis) rather than correcting the underlying capillary pressure mechanism — it also reduces intravascular volume, potentially worsening orthostatic hypotension in an elderly patient; adding a RAAS inhibitor is mechanistically more appropriate.
Option D: Option D is incorrect because CCB-induced ankle edema, while benign in the sense of not indicating heart failure, does cause significant discomfort and functional limitation and warrants pharmacological management when it is uncomfortable.
Option E: Option E is incorrect because spironolactone does not specifically counteract the hemodynamic mechanism of CCB edema through aldosterone blockade — CCB edema is a capillary hydrostatic pressure phenomenon, not aldosterone-mediated sodium retention; spironolactone is used for resistant hypertension management and edema in heart failure and liver disease, not as first-line for CCB edema.

14. An 80-year-old man with ISH is reviewed for medication reconciliation. His medication list includes ibuprofen 400 mg three times daily for knee osteoarthritis, started 6 weeks ago. His BP has risen from a previously controlled 138 mmHg to 158 mmHg on the same antihypertensive regimen. Which of the following best explains this BP elevation and the most appropriate management?

A) Ibuprofen inhibits renal prostaglandins, causing sodium and water retention that directly antagonizes the natriuretic and antihypertensive effects of his diuretic and other antihypertensives — NSAIDs are a common and under-recognized cause of apparent resistance in elderly hypertensive patients; the most appropriate intervention is to substitute ibuprofen with acetaminophen (paracetamol) for his osteoarthritis pain, which provides analgesia without prostaglandin inhibition and does not affect BP; if NSAIDs cannot be avoided, topical diclofenac gel for knee pain minimizes systemic prostaglandin inhibition.
B) Ibuprofen directly activates the mineralocorticoid receptor, causing aldosterone-like sodium retention that specifically antagonizes the effect of ACEi and ARBs but not thiazide diuretics or CCBs — the appropriate intervention is to switch from ibuprofen to indomethacin, which does not activate the mineralocorticoid receptor.
C) Ibuprofen increases BP through COX-1-mediated thromboxane A2 production causing systemic vasoconstriction — the appropriate intervention is to switch to a selective COX-2 inhibitor (celecoxib), which does not inhibit COX-1 and therefore has no cardiovascular or antihypertensive effects.
D) Ibuprofen reduces BP through anti-inflammatory prostaglandin inhibition — the BP rise represents the patient's natural hypertension progression unrelated to the ibuprofen; the antihypertensive regimen should be intensified.
E) Ibuprofen competitively inhibits the tubular secretion of chlorthalidone, raising its plasma concentration and paradoxically increasing BP through chlorthalidone accumulation — the appropriate intervention is to separate the dosing times of ibuprofen and chlorthalidone by 4 hours.

ANSWER: A

Rationale:

The temporal association between ibuprofen initiation (6 weeks ago) and BP elevation (from 138 mmHg to 158 mmHg on the same antihypertensive regimen) strongly implicates ibuprofen as the cause — a classic presentation of NSAID-induced apparent resistance in an elderly hypertensive patient. The mechanism is prostaglandin inhibition in the kidney: renal prostaglandins (PGE2, PGI2) promote natriuresis and maintain renal perfusion in states of volume contraction; COX inhibition by ibuprofen reduces prostaglandin synthesis, causing sodium and water retention, increased vascular tone, and blunting of the antihypertensive response to diuretics and RAAS inhibitors. The treatment is to remove the offending agent. Acetaminophen provides analgesia without COX inhibition and without antihypertensive-antagonism effect — it is the appropriate first-line substitute for musculoskeletal pain in elderly hypertensive patients on antihypertensives. Topical diclofenac gel for knee osteoarthritis is another option — topical NSAIDs provide local anti-inflammatory effect with minimal systemic absorption, minimizing the systemic prostaglandin inhibition effect on BP.

Option B: Option B is incorrect because NSAIDs do not directly activate the mineralocorticoid receptor — their BP effect is through renal prostaglandin inhibition causing sodium retention; and indomethacin is a non-selective COX inhibitor with the same mechanism.
Option C: Option C is incorrect because selective COX-2 inhibitors (celecoxib) still inhibit renal COX-2-derived prostaglandins and carry similar antihypertensive-antagonism and cardiovascular risk — they are not pharmacologically safe alternatives to non-selective NSAIDs for this purpose; and the mechanism is not COX-1-mediated thromboxane vasoconstriction.
Option D: Option D is incorrect because the temporal association with ibuprofen initiation is highly specific — NSAID-induced BP elevation is a well-established and common clinical phenomenon; attributing the BP rise to natural hypertension progression would miss a reversible pharmacological cause.
Option E: Option E is incorrect because ibuprofen does not competitively inhibit chlorthalidone tubular secretion — this pharmacokinetic interaction is fabricated; and higher chlorthalidone concentrations would be expected to lower BP, not raise it.

15. Which of the following correctly identifies the non-pharmacological strategies that are appropriate adjuncts to antihypertensive drug therapy for managing orthostatic hypotension in an elderly patient?

A) Non-pharmacological management of orthostatic hypotension consists exclusively of increased dietary sodium intake — sodium loading expands intravascular volume, correcting the volume deficit that causes all cases of orthostatic hypotension.
B) Non-pharmacological management of orthostatic hypotension consists exclusively of lying flat for 30 minutes after meals — postprandial hypotension is the dominant cause of OH in elderly patients and recumbency eliminates it; other positional strategies are unnecessary.
C) Non-pharmacological strategies have no proven benefit for orthostatic hypotension in elderly patients — pharmacological treatment with midodrine is the only effective approach and should be initiated at the first measurement of orthostatic hypotension in any elderly patient.
D) Non-pharmacological management of orthostatic hypotension is appropriate only in patients with neurogenic OH — in elderly hypertensive patients, OH is exclusively pharmacological and non-pharmacological strategies have no effect on drug-induced OH.
E) Appropriate non-pharmacological strategies for orthostatic hypotension in elderly hypertensive patients include: advice on slow positional changes (sit at the bed edge for 1–2 minutes before standing, particularly in the morning); ensuring adequate hydration (elderly patients are prone to underdrinking); reviewing medication timing (avoiding diuretics in the evening; taking antihypertensives at bedtime rather than morning); avoiding triggers (large meals, alcohol, hot showers, prolonged standing); compression stockings for lower extremity venous pooling; and physical counter-maneuvers (leg crossing, calf muscle pumping) before rising; these measures can meaningfully reduce OH episodes and should be implemented alongside antihypertensive dose adjustment.

ANSWER: E

Rationale:

Non-pharmacological management of orthostatic hypotension is an important and evidence-supported component of care in elderly hypertensive patients — it should be implemented alongside (or instead of, in milder cases) pharmacological adjustments. The evidence-based strategies address the multiple physiological mechanisms contributing to OH in the elderly: slow positional changes prevent the sudden cardiac output demand that overwhelms the blunted baroreceptor response — sitting at the bed edge for 1–2 minutes allows gradual compensation before full upright posture; adequate hydration maintains intravascular volume, which is particularly relevant in the morning after overnight fluid losses; medication timing optimization (avoiding diuretics in the evening, taking antihypertensives at bedtime rather than morning when OH is worst) reduces the peak pharmacological burden during vulnerable periods; avoiding triggers (large meals divert blood flow to the splanchnic bed; alcohol causes vasodilation; hot water causes skin vasodilation; prolonged standing allows venous pooling); compression stockings (graduated compression to the thigh level) reduce venous pooling in the lower extremities and improve venous return; and physical counter-maneuvers (calf muscle contractions, leg crossing, squatting) activate the skeletal muscle pump and improve venous return before rising.

Option A: Option A is incorrect because increased dietary sodium is one component of management — but exclusively focusing on sodium loading misses the comprehensive range of effective non-pharmacological strategies; and excessive sodium intake has its own cardiovascular risks in elderly hypertensive patients.
Option B: Option B is incorrect because postprandial hypotension is one contributor but not the sole cause of OH in the elderly; focusing exclusively on post-meal recumbency while ignoring morning rising, medication timing, and other strategies misrepresents the management approach.
Option C: Option C is incorrect because non-pharmacological strategies have documented benefit for OH in elderly patients — and midodrine carries significant risks (supine hypertension, headache, urinary retention) that make it a later-line intervention, not first-line for all OH.
Option D: Option D is incorrect because non-pharmacological strategies benefit elderly patients with drug-induced OH as well as neurogenic OH — the physiological maneuvers address the common downstream mechanisms regardless of the primary cause.

16. A 91-year-old woman with Clinical Frailty Scale 7 (severely frail, dependent in most activities of daily living) has a sitting BP of 168/64 mmHg on amlodipine 5 mg and indapamide 1.25 mg. She has had three falls in the past 6 months. Her daughter, who is her primary carer, reports she has been confused about her medications. Which of the following best describes the pharmacological management approach?

A) Add a third antihypertensive agent — a patient with a sitting BP of 168 mmHg has substantially elevated cardiovascular risk and requires intensification of therapy regardless of frailty or falls history.
B) Maintain current therapy and add midodrine for the falls — the antihypertensive medications are not causing the falls; midodrine will improve postural BP stability and allow the antihypertensives to continue.
C) Switch to clonidine monotherapy — centrally acting agents are preferred in severely frail elderly patients because they lower BP without peripheral effects; clonidine provides reliable BP reduction without falls risk.
D) Consider de-prescribing — in a severely frail 91-year-old (CFS 7) with three falls in 6 months and medication confusion, the immediate risks from antihypertensive therapy (falls, fracture, cognitive adverse effects from polypharmacy) likely outweigh the long-term cardiovascular benefit; a shared decision-making discussion with the patient and daughter should explore gradual withdrawal of one or both antihypertensives with BP monitoring; life expectancy at CFS 7 may be insufficient to derive cardiovascular benefit from BP control at this age; the primary goal shifts to quality of life, fall prevention, and symptom management.
E) Continue current therapy unchanged — ESH 2023 recommends treatment above age 80 regardless of frailty; guideline targets override clinical individualization and the antihypertensives should not be adjusted.

ANSWER: D

Rationale:

This 91-year-old woman with CFS 7 (severely frail) and three falls in 6 months represents the paradigmatic case for antihypertensive de-prescribing. Several factors inform this decision: CFS 7 indicates severe frailty with dependency in most activities of daily living — physiological reserve is severely limited; three falls in 6 months is a high-risk pattern indicating the fall prevention imperative now outweighs routine cardiovascular risk reduction; medication confusion in a severely frail cognitively impaired patient means the medications are causing harm through confusion and potentially through non-adherence-related BP variability; life expectancy at 91 with CFS 7 is substantially limited — the long-term cardiovascular benefit from BP control (which accrues over years) may not be reachable before the more immediate harms of antihypertensive polypharmacy occur; and the primary goals of care in severely frail elderly patients shift appropriately toward quality of life, symptom management, and fall prevention. De-prescribing should proceed through shared decision-making with the patient (if she has capacity) and her daughter, with gradual tapering of one agent at a time and BP monitoring.

Option A: Option A is incorrect because intensifying therapy in a severely frail patient with recurrent falls would further increase the adverse-effect burden — the correct direction of pharmacological change in CFS 7 is de-escalation.
Option B: Option B is incorrect because midodrine (a peripheral alpha-1 agonist vasopressor) adds another medication with its own risks (supine hypertension, urinary retention) rather than addressing the root problem of excessive antihypertensive burden; and it does not address the medication confusion.
Option C: Option C is incorrect because clonidine is specifically one of the agents most to be avoided in elderly patients due to CNS adverse effects and dangerous rebound hypertension on discontinuation — it is the opposite of appropriate in a frail elderly patient with falls and medication confusion.
Option E: Option E is incorrect because guidelines explicitly recommend individualization in frail elderly patients — ESH 2023 specifically states that very frail patients (CFS 6–8) require individualized targets with quality-of-life focus; guidelines do not override clinical judgment in severely frail elderly patients.